Skip to content
Research Article Open access CC BY 4.0

The Vicious Cycle of BRASH Syndrome: A Case Report and a Brief Review of Literature

Charif H., Patrick M., Njie M., Jama D., B. E. Ovaga, Haboub M., Arous S., Bennouna E. M., Drighil A., Habbal R.

Asian Journal of Research in Cardiovascular Diseases · pp. 136–139 · Published 26 Sep 2023

Abstract

BRASH syndrome is a medical condition characterized by the combination of bradycardia (a slow heart rate) and shock in individuals with renal failure, a history of taking atrioventricular (AV) nodal blocking medications, and hyperkalemia (elevated levels of potassium in the blood). This syndrome typically occurs in elderly individuals who have compromised kidney function and a history of regularly using AV nodal blocking medications [1]. Major risk factors for BRASH syndrome include hypovolemia (low blood volume) and worsening kidney function. It's important to recognize that these manifestations should be considered as part of a syndrome rather than isolated findings, as they are interconnected and have synergistic effects on each other. These underlying physiological processes create a harmful cycle of bradycardia and reduced cardiac output, leading to organ dysfunction, including renal failure with hyperkalemia, which in turn exacerbates the bradycardia. BRASH syndrome is associated with significant morbidity and mortality [2].Typically, the treatment approach for BRASH syndrome involves increasing renal blood flow by enhancing cardiac output through the administration of catecholamines. In rare cases, interventions such as intralipid emulsion and continuous renal replacement therapy (CRRT) may be necessary, depending on the specific circumstances. Early recognition of BRASH syndrome is crucial, as it can help prevent diagnostic delays and reduce mortality rates. In the case presented here, the patient's medical history provided important clues that led to the early identification and aggressive treatment of BRASH syndrome. This timely intervention prevented the onset of shock, reduced morbidity, and improved overall outcomes.

Atrioventricular node blocker bradycardia BRASH hyperkalemia renal failure shock

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.